← SynDRA
Urmc-099
SynDRA canonical compound SYN0053661 — structure-anchored drug synonym record
Clinical phase
Preclinical
Primary target(s)
CDKL2 | DAPK3 | FLT3 | LRRK2 | MAP3K10 | MAP3K11 | MAP3K2 | MAP3K9 | SRPK2
Mechanism of action
mixed lineage kinase inhibitor
All known targets
CDKL2
DAPK3
FLT3
LRRK2
MAP3K10
MAP3K11
MAP3K2
MAP3K9
SRPK2
Mechanisms of action (all sources)
CDKL2 INHIBITOR
DAPK3 INHIBITOR
FLT3 INHIBITOR
LRRK2 INHIBITOR
MAP3K10 INHIBITOR
MAP3K11 INHIBITOR
MAP3K2 INHIBITOR
MAP3K9 INHIBITOR
SRPK2 INHIBITOR
mixed lineage kinase inhibitor
Cross-references
PubChem CID:
54764565
ChEMBL:
CHEMBL2436978
TTD: D07ADX
Synonyms
URMC-099-C
URMC099
compound 1 [PMID 24044867]
RefChem:193311
MFCD28168077
C27H27N5
SCHEMBL722076
GTPL8106
orb1301112
SCHEMBL30529948
SCHEMBL30529949
SCHEMBL30529950
SCHEMBL30529951
URMC-099?
QKKIWEILHCXECO-UHFFFAOYSA-N
GLXC-04935
HMS3674I17
EX-A1276
BDBM50441567
s7343
AKOS025404701
CCG-268902
EBC-157209
NCGC00386408-01
NCGC00386408-03
AC-33141
AS-16339
DA-47011
FU170951
HY-12599
SY242127
T6057
BRD-K66908976-001-01-8
Z2831763793
Look up Urmc-099 in the interactive SynDRA portal →